Eiger BioPharmaceuticals Inc Watch

from 8-K 61 pages Lambda Asset Purchase Agreement by and Between Eiger Innotherapeutics, Inc., as Purchaser, and Eiger Biopharmaceuticals, Inc., as Seller Dated as of August 1, 2024

from 8-K 68 pages Lonafarnib Asset Purchase Agreement by and Between Eiger Innotherapeutics, Inc., as Purchaser, and Eiger Biopharmaceuticals, Inc., as Seller Dated as of August 1, 2024

from 8-K 55 pages Asset Purchase Agreement by and Between Amylyx Pharmaceuticals, Inc., or a Wholly Owned Subsidiary Thereof, as Purchaser, and Eiger Biopharmaceuticals, Inc., as Seller Dated as of June 21, 2024

from 8-K 48 pages Asset Purchase Agreement by and Between Spruce Biosciences, Inc., as Purchaser, and Eiger Biopharmaceuticals, Inc., as Seller Dated as of June 13, 2024

from 10-K/A 1 page Eiger Biopharmaceuticals, Inc. Amended 2021 Inducement Plan

from 8-K 64 pages Asset Purchase Agreement by and Between Sentynl Therapeutics, Inc., as Purchaser, and Eiger Biopharmaceuticals, Inc., as Seller Dated as of March 31, 2024

from 10-Q 1 page I Hereby Accept This Promotion at Eiger Biopharmaceuticals, Inc. I Understand and Agree That My Employment With the Company Continues to Be Voluntarily and That I May Resign at Any Time. Similarly, My Employment May Be Terminated for Any Reason and at Any Time Without Previous Notice. I Understand This Promotion Letter Constitutes Employment “At-Will” and No Contractual Relationship or Actionable Promises Exist Between the Employer and Employee. This Term of Employment Is Not Subject to Change or Modification of Any Kind Except in Writing and Signed by the Senior Director of Human Resources and the Chief Executive Officer of Eiger Biopharmaceuticals, Inc. /S/ Ingrid Choong 9/20/2023 Signature Date Ingrid Choong

from 10-Q 7 pages 25 November 2019 Eiger Biopharmaceuticals, Inc. 2155 Park Boulevard Palo Alto, Ca 94306 Ingrid Choong, PH.D. Re: Employment Terms Dear Dr. Choong, Eiger Biopharmaceuticals, Inc. (“Eiger” or the “Company”) Is Pleased to Offer the Following Terms to Govern Your Continued Employment in This Letter Agreement (“Agreement”). Duties, Compensation and Benefits You Will Continue to Serve as the Senior Vice President, Clinical Development, Reporting to the Chief Executive Officer. You Will Work at Our Facility Located at 2155 Park Boulevard in Palo Alto, California. Your Salary Will Be $300,000 Per Year, Less Payroll Deductions and Withholdings. You Will Be Paid Semimonthly, or in Accordance With Company’s Compensation Practices for Other Employees in Place at the Time

from 10-Q 9 pages Consulting Agreement

from 10-Q 8 pages March 31, 2023 Jim Vollins

from 8-K 18 pages June 28, 2023 via Electronic Mail David Apelian, MD, Phd, Mba Re: Amended and Restated Employment Terms Dear Dr. Apelian,

from 10-K 2 pages Second Amendment to Lease

from 10-K 13 pages January 9, 2023 via Electronic Mail (Davidapelian@gmail.com) David Apelian, MD, Phd, Mba 3 Old Beach Glen Road Boonton, New Jersey 07005 Re: Interim CEO Employment Terms Dear Dr. Apelian, Eiger Biopharmaceuticals, Inc. (“Eiger” or the “Company”) Is Pleased to Offer Employment to You on the Following Terms of This Offer Letter Agreement (“Agreement”): Duties

from 10-K 10 pages Separation Agreement and General Release

from 8-K 15 pages Eiger Biopharmaceuticals, Inc. Common Stock Purchase Agreement

from 10-Q 8 pages Re:employment Terms Dear Mr. Atkisson, Eiger Biopharmaceuticals, Inc. (“Eiger” or the “Company”) Is Pleased to Offer You Employment on the Following Terms of This Offer Letter Agreement (“Agreement”). Duties, Compensation and Benefits You Will Serve as the General Counsel, Corporate Secretary, and Chief Compliance Officer, Reporting to the President and CEO. You Will Work at Our Facility Located at 2155 Park Boulevard in Palo Alto, California. Your Salary Will Be $390,000 Per Year, Less Payroll Deductions and Withholdings. You Will Be Paid Semi-Monthly, or in Accordance With Company’s Compensation Practices for Other Employees in Place at the Time

from 10-Q 2 pages Eiger Biopharmaceuticals, Inc. 2021 Inducement Plan

from 10-Q 10 pages Eiger Biopharmaceuticals, Inc. Restricted Stock Unit Award Grant Notice 2013 Equity Incentive Plan

from 10-K ~5 pages Amendment #7 to License Agreement

from 10-K 34 pages Asset Purchase Agreement by and Between Abbvie Inc. and Eiger Biopharmaceuticals, Inc. November 20, 2020